
New Delhi, 21 April 2021
As per news report of Reuters, Roche and Boston-based partner Atea Pharmaceuticals (AVIR.O) are hoping their AT-527 pill could offer an anti-viral therapy to treat COVID-19 patients that would be easier to administer and cheaper than other prospective treatments, such as antibody cocktails or Gilead Science's (GILD.O) remdesivir.
Source -reuters.com
If you like the story and if you wish more such stories, support our effort Make a donation.

Wed Apr 21 2021 | By Newsdesk

Wed Apr 21 2021 | By Newsdesk

Wed Apr 21 2021 | By Newsdesk


Wed Apr 21 2021 | By Newsdesk